262 related articles for article (PubMed ID: 35946495)
21. A radiopharmaceutical [
Tang Y; Hu Y; Liu W; Chen L; Zhao Y; Ma H; Yang J; Yang Y; Liao J; Cai J; Chen Y; Liu N
Nucl Med Biol; 2019 Mar; 70():23-31. PubMed ID: 30826708
[TBL] [Abstract][Full Text] [Related]
22. First-in-Human Evaluation of Site-Specifically Labeled
Yeh R; O'Donoghue JA; Jayaprakasam VS; Mauguen A; Min R; Park S; Brockway JP; Bromberg JF; Zhi WI; Robson ME; Sanford R; Modi S; Agnew BJ; Lyashchenko SK; Lewis JS; Ulaner GA; Zeglis BM
J Nucl Med; 2024 Mar; 65(3):386-393. PubMed ID: 38272704
[TBL] [Abstract][Full Text] [Related]
23. Immuno-PET Imaging of CD30-Positive Lymphoma Using 89Zr-Desferrioxamine-Labeled CD30-Specific AC-10 Antibody.
Rylova SN; Del Pozzo L; Klingeberg C; Tönnesmann R; Illert AL; Meyer PT; Maecke HR; Holland JP
J Nucl Med; 2016 Jan; 57(1):96-102. PubMed ID: 26514172
[TBL] [Abstract][Full Text] [Related]
24.
Price EW; Carnazza KE; Carlin SD; Cho A; Edwards KJ; Sevak KK; Glaser JM; de Stanchina E; Janjigian YY; Lewis JS
J Nucl Med; 2017 Sep; 58(9):1386-1394. PubMed ID: 28280216
[TBL] [Abstract][Full Text] [Related]
25. p-SCN-Bn-HOPO: A Superior Bifunctional Chelator for (89)Zr ImmunoPET.
Deri MA; Ponnala S; Kozlowski P; Burton-Pye BP; Cicek HT; Hu C; Lewis JS; Francesconi LC
Bioconjug Chem; 2015 Dec; 26(12):2579-91. PubMed ID: 26550847
[TBL] [Abstract][Full Text] [Related]
26. Sortase-Mediated Site-Specific Conjugation and
Fay R; Törő I; Schinke AL; Simic B; Schaefer JV; Dreier B; Plückthun A; Holland JP
Mol Pharm; 2022 Oct; 19(10):3576-3585. PubMed ID: 35434995
[TBL] [Abstract][Full Text] [Related]
27. Immuno-PET Imaging of the Programmed Cell Death-1 Ligand (PD-L1) Using a Zirconium-89 Labeled Therapeutic Antibody, Avelumab.
Jagoda EM; Vasalatiy O; Basuli F; Opina ACL; Williams MR; Wong K; Lane KC; Adler S; Ton AT; Szajek LP; Xu B; Butcher D; Edmondson EF; Swenson RE; Greiner J; Gulley J; Eary J; Choyke PL
Mol Imaging; 2019; 18():1536012119829986. PubMed ID: 31044647
[TBL] [Abstract][Full Text] [Related]
28. Site-Specific
Yue TTC; Ge Y; Aprile FA; Ma MT; Pham TT; Long NJ
Bioconjug Chem; 2023 Oct; 34(10):1802-1810. PubMed ID: 37751398
[TBL] [Abstract][Full Text] [Related]
29. Tripodal tris(hydroxypyridinone) ligands for immunoconjugate PET imaging with (89)Zr(4+): comparison with desferrioxamine-B.
Ma MT; Meszaros LK; Paterson BM; Berry DJ; Cooper MS; Ma Y; Hider RC; Blower PJ
Dalton Trans; 2015 Mar; 44(11):4884-900. PubMed ID: 25351250
[TBL] [Abstract][Full Text] [Related]
30. Thiol-Reactive Bifunctional Chelators for the Creation of Site-Selectively Modified Radioimmunoconjugates with Improved Stability.
Adumeau P; Davydova M; Zeglis BM
Bioconjug Chem; 2018 Apr; 29(4):1364-1372. PubMed ID: 29509393
[TBL] [Abstract][Full Text] [Related]
31. Total-Body PET and Highly Stable Chelators Together Enable Meaningful
Berg E; Gill H; Marik J; Ogasawara A; Williams S; van Dongen G; Vugts D; Cherry SR; Tarantal AF
J Nucl Med; 2020 Mar; 61(3):453-460. PubMed ID: 31562219
[TBL] [Abstract][Full Text] [Related]
32. Evaluation and selection of a lead diabody for interferon-γ PET imaging.
Rezazadeh F; Ramos N; Saliganan AD; Barr S; Peraino N; Schomburg F; Rancour D; Viola NT
Nucl Med Biol; 2022; 114-115():162-167. PubMed ID: 35753939
[TBL] [Abstract][Full Text] [Related]
33. Advancing
Wuensche TE; Stergiou N; Mes I; Verlaan M; Schreurs M; Kooijman EJM; Janssen B; Windhorst AD; Jensen A; Asuni AA; Bang-Andersen B; Beaino W; Dongen GAMS; Vugts DJ
Theranostics; 2022; 12(16):7067-7079. PubMed ID: 36276653
[TBL] [Abstract][Full Text] [Related]
34. Site-Specifically Conjugated Single-Domain Antibody Successfully Identifies Glypican-3-Expressing Liver Cancer by Immuno-PET.
Fayn S; King AP; Gutsche NT; Duan Z; Buffington J; Olkowski CP; Fu Y; Hong J; Sail D; Baidoo KE; Swenson RE; Cheloha RW; Ho M; Choyke PL; Escorcia FE
J Nucl Med; 2023 Jul; 64(7):1017-1023. PubMed ID: 36997331
[TBL] [Abstract][Full Text] [Related]
35. Trastuzumab-conjugated oxine-based ligand for [
Southcott L; Wharton L; Rousseau J; Merkens H; Yang H; Bénard F; Orvig C
J Inorg Biochem; 2022 Oct; 235():111936. PubMed ID: 35878576
[TBL] [Abstract][Full Text] [Related]
36. Leveraging a Dual Variable Domain Immunoglobulin to Create a Site-Specifically Modified Radioimmunoconjugate.
MacPherson DS; Hwang D; Sarrett SM; Keinänen O; Rodriguez C; Rader C; Zeglis BM
Mol Pharm; 2023 Jan; 20(1):775-782. PubMed ID: 36377696
[TBL] [Abstract][Full Text] [Related]
37. Cyclic versus Noncyclic Chelating Scaffold for
Summer D; Garousi J; Oroujeni M; Mitran B; Andersson KG; Vorobyeva A; Löfblom J; Orlova A; Tolmachev V; Decristoforo C
Mol Pharm; 2018 Jan; 15(1):175-185. PubMed ID: 29160082
[TBL] [Abstract][Full Text] [Related]
38. p-Isothiocyanatobenzyl-desferrioxamine: a new bifunctional chelate for facile radiolabeling of monoclonal antibodies with zirconium-89 for immuno-PET imaging.
Perk LR; Vosjan MJ; Visser GW; Budde M; Jurek P; Kiefer GE; van Dongen GA
Eur J Nucl Med Mol Imaging; 2010 Feb; 37(2):250-9. PubMed ID: 19763566
[TBL] [Abstract][Full Text] [Related]
39. In Vivo Characterization of Platinum(II)-Based Linker Technology for the Development of Antibody-Drug Conjugates: Taking Advantage of Dual Labeling with
Muns JA; Montserrat V; Houthoff HJ; Codée-van der Schilden K; Zwaagstra O; Sijbrandi NJ; Merkul E; van Dongen GAMS
J Nucl Med; 2018 Jul; 59(7):1146-1151. PubMed ID: 29496986
[TBL] [Abstract][Full Text] [Related]
40. Chemoenzymatic strategy for the synthesis of site-specifically labeled immunoconjugates for multimodal PET and optical imaging.
Zeglis BM; Davis CB; Abdel-Atti D; Carlin SD; Chen A; Aggeler R; Agnew BJ; Lewis JS
Bioconjug Chem; 2014 Dec; 25(12):2123-8. PubMed ID: 25418333
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
